APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biopharmaceuticals for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Biopharmaceuticals for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025184 pages

Choose your research edition.

Industry ResearchBiopharmaceuticals for Psoriasis Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Biopharmaceuticals for Psoriasis Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Biopharmaceuticals for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biopharmaceuticals for Psoriasis Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Biopharmaceuticals for Psoriasis Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Biopharmaceuticals for Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Biopharmaceuticals for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biopharmaceuticals for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biopharmaceuticals for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Biopharmaceuticals for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biopharmaceuticals for Psoriasis include Johnson & Johnson, Eli Lilly, Pfizer, AbbVie, UCB, Organon and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biopharmaceuticals for Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biopharmaceuticals for Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biopharmaceuticals for Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biopharmaceuticals for Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Biopharmaceuticals for Psoriasis Segment by Company

Johnson & Johnson

Eli Lilly

Pfizer

AbbVie

UCB

Organon

Amgen

Biopharmaceuticals for Psoriasis Segment by Type

TNF-α

Interleukin-17

Interleukin-23

Other

Biopharmaceuticals for Psoriasis Segment by Application

Hospital

Clinic

Other

Biopharmaceuticals for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biopharmaceuticals for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biopharmaceuticals for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biopharmaceuticals for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biopharmaceuticals for Psoriasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biopharmaceuticals for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biopharmaceuticals for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biopharmaceuticals for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biopharmaceuticals for Psoriasis Industry Trends Table 2. Biopharmaceuticals for Psoriasis Industry Drivers Table 3. Biopharmaceuticals for Psoriasis Industry Opportunities and Challenges Table 4. Biopharmaceuticals for Psoriasis Industry Restraints Table 5. Global Biopharmaceuticals for Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biopharmaceuticals for Psoriasis Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Biopharmaceuticals for Psoriasis Sales Market Share by Manufacturers Table 9. Global Biopharmaceuticals for Psoriasis Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Biopharmaceuticals for Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biopharmaceuticals for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biopharmaceuticals for Psoriasis Manufacturers, Product Type & Application Table 13. Global Biopharmaceuticals for Psoriasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biopharmaceuticals for Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of TNF-α Table 17. Major Manufacturers of Interleukin-17 Table 18. Major Manufacturers of Interleukin-23 Table 19. Major Manufacturers of Other Table 20. Global Biopharmaceuticals for Psoriasis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Biopharmaceuticals for Psoriasis Sales by Type (2021-2026) & (K Units) Table 22. Global Biopharmaceuticals for Psoriasis Sales by Type (2027-2032) & (K Units) Table 23. Global Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2026) Table 24. Global Biopharmaceuticals for Psoriasis Sales Market Share by Type (2027-2032) Table 25. Global Biopharmaceuticals for Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Biopharmaceuticals for Psoriasis Revenue by Type (2021-2026) & (K Units) Table 27. Global Biopharmaceuticals for Psoriasis Revenue by Type (2027-2032) & (K Units) Table 28. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Type (2021-2026) Table 29. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Other Table 33. Global Biopharmaceuticals for Psoriasis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Biopharmaceuticals for Psoriasis Sales by Application (2021-2026) & (K Units) Table 35. Global Biopharmaceuticals for Psoriasis Sales by Application (2027-2032) & (K Units) Table 36. Global Biopharmaceuticals for Psoriasis Sales Market Share by Application (2021-2026) Table 37. Global Biopharmaceuticals for Psoriasis Sales Market Share by Application (2027-2032) Table 38. Global Biopharmaceuticals for Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Biopharmaceuticals for Psoriasis Revenue by Application (2021-2026) & (K Units) Table 40. Global Biopharmaceuticals for Psoriasis Revenue by Application (2027-2032) & (K Units) Table 41. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Application (2021-2026) Table 42. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Application (2027-2032) Table 43. Global Biopharmaceuticals for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Biopharmaceuticals for Psoriasis Sales by Region (2021-2026) & (K Units) Table 45. Global Biopharmaceuticals for Psoriasis Sales Market Share by Region (2021-2026) Table 46. Global Biopharmaceuticals for Psoriasis Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Biopharmaceuticals for Psoriasis Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Biopharmaceuticals for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Biopharmaceuticals for Psoriasis Sales by Country (2021-2026) & (K Units) Table 50. North America Biopharmaceuticals for Psoriasis Sales by Country (2027-2032) & (K Units) Table 51. Europe Biopharmaceuticals for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Biopharmaceuticals for Psoriasis Sales by Country (2021-2026) & (K Units) Table 53. Europe Biopharmaceuticals for Psoriasis Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Biopharmaceuticals for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Biopharmaceuticals for Psoriasis Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Biopharmaceuticals for Psoriasis Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Biopharmaceuticals for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Biopharmaceuticals for Psoriasis Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Biopharmaceuticals for Psoriasis Sales by Country (2027-2032) & (K Units) Table 60. Global Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Biopharmaceuticals for Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Biopharmaceuticals for Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Region (2021-2026) Table 64. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Region (2027-2032) Table 65. Johnson & Johnson Company Information Table 66. Johnson & Johnson Business Overview Table 67. Johnson & Johnson Biopharmaceuticals for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Johnson & Johnson Biopharmaceuticals for Psoriasis Product Portfolio Table 69. Johnson & Johnson Recent Development Table 70. Eli Lilly Company Information Table 71. Eli Lilly Business Overview Table 72. Eli Lilly Biopharmaceuticals for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Eli Lilly Biopharmaceuticals for Psoriasis Product Portfolio Table 74. Eli Lilly Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Biopharmaceuticals for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer Biopharmaceuticals for Psoriasis Product Portfolio Table 79. Pfizer Recent Development Table 80. AbbVie Company Information Table 81. AbbVie Business Overview Table 82. AbbVie Biopharmaceuticals for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. AbbVie Biopharmaceuticals for Psoriasis Product Portfolio Table 84. AbbVie Recent Development Table 85. UCB Company Information Table 86. UCB Business Overview Table 87. UCB Biopharmaceuticals for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. UCB Biopharmaceuticals for Psoriasis Product Portfolio Table 89. UCB Recent Development Table 90. Organon Company Information Table 91. Organon Business Overview Table 92. Organon Biopharmaceuticals for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Organon Biopharmaceuticals for Psoriasis Product Portfolio Table 94. Organon Recent Development Table 95. Amgen Company Information Table 96. Amgen Business Overview Table 97. Amgen Biopharmaceuticals for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Amgen Biopharmaceuticals for Psoriasis Product Portfolio Table 99. Amgen Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Biopharmaceuticals for Psoriasis Distributors List Table 103. Biopharmaceuticals for Psoriasis Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Biopharmaceuticals for Psoriasis Product Image Figure 2. Global Biopharmaceuticals for Psoriasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biopharmaceuticals for Psoriasis Market Size (2021-2032) & (US$ Million) Figure 4. Global Biopharmaceuticals for Psoriasis Sales (2021-2032) & (K Units) Figure 5. Global Biopharmaceuticals for Psoriasis Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Biopharmaceuticals for Psoriasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. TNF-α Image Figure 9. Interleukin-17 Image Figure 10. Interleukin-23 Image Figure 11. Other Image Figure 12. Global Biopharmaceuticals for Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Biopharmaceuticals for Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2032) Figure 15. Global Biopharmaceuticals for Psoriasis Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Biopharmaceuticals for Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global Biopharmaceuticals for Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Biopharmaceuticals for Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Biopharmaceuticals for Psoriasis Sales Market Share by Application (2021-2032) Figure 24. Global Biopharmaceuticals for Psoriasis Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Biopharmaceuticals for Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Application (2021-2032) Figure 27. North America Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Biopharmaceuticals for Psoriasis Sales Market Share by Country (2021-2032) Figure 29. U.S. Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Biopharmaceuticals for Psoriasis Sales Market Share by Country (2021-2032) Figure 34. Germany Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Biopharmaceuticals for Psoriasis Sales Market Share by Country (2021-2032) Figure 41. China Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Biopharmaceuticals for Psoriasis Sales Market Share by Country (2021-2032) Figure 49. Brazil Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Biopharmaceuticals for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Biopharmaceuticals for Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Biopharmaceuticals for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 60. North America Biopharmaceuticals for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Biopharmaceuticals for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 62. Europe Biopharmaceuticals for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Biopharmaceuticals for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Biopharmaceuticals for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Biopharmaceuticals for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Biopharmaceuticals for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Biopharmaceuticals for Psoriasis Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Biopharmaceuticals for Psoriasis Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • TNF-α
  • Interleukin-17
  • Interleukin-23
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Johnson & Johnson
  • Eli Lilly
  • Pfizer
  • AbbVie
  • UCB
  • Organon
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biopharmaceuticals for Psoriasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biopharmaceuticals for Psoriasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biopharmaceuticals for Psoriasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biopharmaceuticals for Psoriasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biopharmaceuticals for Psoriasis Market Dynamics
  1. 2.1 Biopharmaceuticals for Psoriasis Industry Trends
  2. 2.2 Biopharmaceuticals for Psoriasis Industry Drivers
  3. 2.3 Biopharmaceuticals for Psoriasis Industry Opportunities and Challenges
  4. 2.4 Biopharmaceuticals for Psoriasis Industry Restraints
3 Biopharmaceuticals for Psoriasis Market by Manufacturers
  1. 3.1 Global Biopharmaceuticals for Psoriasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biopharmaceuticals for Psoriasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biopharmaceuticals for Psoriasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biopharmaceuticals for Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biopharmaceuticals for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biopharmaceuticals for Psoriasis Manufacturers, Product Type & Application
  7. 3.7 Global Biopharmaceuticals for Psoriasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biopharmaceuticals for Psoriasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biopharmaceuticals for Psoriasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biopharmaceuticals for Psoriasis Tier 1, Tier 2, and Tier 3
4 Biopharmaceuticals for Psoriasis Market by Type
  1. 4.1 Biopharmaceuticals for Psoriasis Type Introduction
  2. 4.1.1 TNF-α
  3. 4.1.2 Interleukin-17
  4. 4.1.3 Interleukin-23
  5. 4.1.4 Other
  6. 4.2 Global Biopharmaceuticals for Psoriasis Sales by Type
  7. 4.2.1 Global Biopharmaceuticals for Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Biopharmaceuticals for Psoriasis Sales by Type (2021-2032)
  9. 4.2.3 Global Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2032)
  10. 4.3 Global Biopharmaceuticals for Psoriasis Revenue by Type
  11. 4.3.1 Global Biopharmaceuticals for Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Biopharmaceuticals for Psoriasis Revenue by Type (2021-2032)
  13. 4.3.3 Global Biopharmaceuticals for Psoriasis Revenue Market Share by Type (2021-2032)
5 Biopharmaceuticals for Psoriasis Market by Application
  1. 5.1 Biopharmaceuticals for Psoriasis Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Biopharmaceuticals for Psoriasis Sales by Application
  6. 5.2.1 Global Biopharmaceuticals for Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biopharmaceuticals for Psoriasis Sales by Application (2021-2032)
  8. 5.2.3 Global Biopharmaceuticals for Psoriasis Sales Market Share by Application (2021-2032)
  9. 5.3 Global Biopharmaceuticals for Psoriasis Revenue by Application
  10. 5.3.1 Global Biopharmaceuticals for Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biopharmaceuticals for Psoriasis Revenue by Application (2021-2032)
  12. 5.3.3 Global Biopharmaceuticals for Psoriasis Revenue Market Share by Application (2021-2032)
6 Global Biopharmaceuticals for Psoriasis Sales by Region
  1. 6.1 Global Biopharmaceuticals for Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biopharmaceuticals for Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global Biopharmaceuticals for Psoriasis Sales by Region (2021-2026)
  4. 6.2.2 Global Biopharmaceuticals for Psoriasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biopharmaceuticals for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biopharmaceuticals for Psoriasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biopharmaceuticals for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biopharmaceuticals for Psoriasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biopharmaceuticals for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biopharmaceuticals for Psoriasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biopharmaceuticals for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biopharmaceuticals for Psoriasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biopharmaceuticals for Psoriasis Revenue by Region
  1. 7.1 Global Biopharmaceuticals for Psoriasis Revenue by Region
  2. 7.1.1 Global Biopharmaceuticals for Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biopharmaceuticals for Psoriasis Revenue by Region (2021-2026)
  4. 7.1.3 Global Biopharmaceuticals for Psoriasis Revenue by Region (2027-2032)
  5. 7.1.4 Global Biopharmaceuticals for Psoriasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biopharmaceuticals for Psoriasis Revenue (2021-2032)
  8. 7.2.2 North America Biopharmaceuticals for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biopharmaceuticals for Psoriasis Revenue (2021-2032)
  11. 7.3.2 Europe Biopharmaceuticals for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biopharmaceuticals for Psoriasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biopharmaceuticals for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biopharmaceuticals for Psoriasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biopharmaceuticals for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Biopharmaceuticals for Psoriasis Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Biopharmaceuticals for Psoriasis Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Biopharmaceuticals for Psoriasis Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Biopharmaceuticals for Psoriasis Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 UCB
  26. 8.5.1 UCB Company Information
  27. 8.5.2 UCB Business Overview
  28. 8.5.3 UCB Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 UCB Biopharmaceuticals for Psoriasis Product Portfolio
  30. 8.5.5 UCB Recent Developments
  31. 8.6 Organon
  32. 8.6.1 Organon Company Information
  33. 8.6.2 Organon Business Overview
  34. 8.6.3 Organon Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Organon Biopharmaceuticals for Psoriasis Product Portfolio
  36. 8.6.5 Organon Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Biopharmaceuticals for Psoriasis Product Portfolio
  42. 8.7.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biopharmaceuticals for Psoriasis Value Chain Analysis
  2. 9.1.1 Biopharmaceuticals for Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biopharmaceuticals for Psoriasis Production Mode & Process
  6. 9.2 Biopharmaceuticals for Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biopharmaceuticals for Psoriasis Distributors
  9. 9.2.3 Biopharmaceuticals for Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst